Pamela Allen
@PamAllenMD1
Followers
512
Following
297
Media
23
Statuses
131
Hematologist/Medical Oncologist @WinshipAtEmory, lymphoma specialist. These opinions are my own
Atlanta, GA
Joined July 2018
Join us in supporting T-cell lymphoma research at Emory! Click the link to join our team for the Winship 5K on October 4th or donate to our program! @KyowaKirin_US @SecuraBio @lymphoma @LLSusa .
secure2.convio.net
Join Us in Advancing T-Cell Lymphoma Research
0
0
3
Oral JAK-1 inhibitor Golidocitinib in r/r PTCL. JACKPOT8 Part B. 44% ORR, with median DOR 20 mo. ~ 60% PTCL, NOS. 94% patients were Asian, very few treated in US. Early promising data, but will need to be confirmed in a US based study.
0
0
8
Meanwhile adult oncology, very high professional fulfillment, but also one of the worst for burnout… sounds about right.
2
0
12
GREAT work from one of our small group mentees, @rmistry91! Shout out to the amazing work being done in medical education through the ASH Medical Educator Institute! #ASHMEI @ASH_hematology @SriNagalla.
Excited to share our pilot study data using @TheFellowOnCall as an educational tool at the @VUmedicine Health Professions Education Research Day! . @VUMC_Medicine @VUMCHemOnc @vpatelmd @DanielHausrath
0
1
3
As a T-cell lymphoma specialist, I can tell you this is exceedingly rare. In an email sent in response to this announcement to T-cell docs at ~ 20 of the largest centers, none of us have seen this. @lymphomaphilia @bpromd @jaehyukchoimd.
Ugh - FDA statement already getting sensationalized in lay media. Here's what I know:.1) Many risk factors for second cancers in #MMsm #lymsm, with or without CAR-T. 2) CAR-T has saved thousands of lives - I will not be changing my practice based on FDA press release sans data.
3
14
81
So proud of you!! I remeber your first oral presentation at USCLC!.
Beyond thankful and humbled to match @MDAndersonNews for hematology/oncology. Still finding the words to truly capture my mentors' selflessness, compassion, and sacrifice. Thank you for seeing potential in me and inspiring my growth throughout residency.
1
0
1
Let's make sure every voter can cast their ballot in the upcoming election!.I just ordered a free, nonpartisan voter badge from @vot_er_org so I can offer patients the opportunity to register to vote or view their ballot right in the clinic. Get yours ⤵️
0
1
4
Important article by @RaphaelESteiner showing reducing the dose of brentuximab in A+ AVD in practice does not seem to impact outcomes. Important when counseling our patients who want to keep on high doses, despite neuropathy!.
Our @CULymphoma faculty Drs. @StevenBairMD & @mana1981 contributed to a new study @BloodAdvances on the impact of brentuximab vedotin dosing on frontline cHL outcomes. #lymsm cc @PamAllenMD1 @DrAEvens @PallawiTorkaMD
0
3
13
RT @DrAEvens: Agree. @DanaFarber Dr LaCasce @DrLaCasce did a marvelous job (w/ beautiful graphics) setting the stage and putting this ple….
0
1
0
RT @Decaturish: @austinlouisray @katiehawk If we can get Decaturish up to 10,000 subscribers, we'll give ATL one of the best digital news w….
0
1
0
Thanks to @ASH_hematology and @abhhoficial for having us at the extraordinary Highlights of ASH in Latin America in São Paulo. Honored to be a part of such a special event - left feeling so inspired by my fellow speakers and our Latin American colleagues. @AmyDeZern @PamAllenMD1
1
1
8
That’s a wrap to Highlights of ASH, Latin America! My first time co-chairing! Thanks to my co-chairs @AmyDeZern for guidance! #HOALA2023 @ASH_hematology
1
1
27
Great morning session at Highlights of ASH- Latin America in São Paulo, Brazil. Learning about Severe Aplastic Anemia, hemophilia, and Car-T #HOALA2023 @ASH_hematology
2
0
12
Amazing!!!. I remember when I was told frontline PD-1 was a crazy concept… fast forward to our ASH presentation of frontline pembro showing perfect outcomes and being told there was not enough interest generated from my presentation to move forward! Merck missed out!.
1
1
22
RT @tvoorheesmd: Nivo-AVD > BV-AVD in advanced stage classical Hodgkin Lymphoma!? . "With a median follow-up of 12.1 months, the PFS was su….
0
3
0
Important PSA. Dupilumab does not work in CTCL! Great work by Dr. Alkilov’s team presented @USCLC #CTCL @WinshipAtEmory
0
0
6
0
0
12
FDA approves zanubrutinib for CLL/SLL any line of therapy! #lymsm
fda.gov
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa, BeiGene USA, Inc.) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
0
0
5